Prior to quantification of exosomal miRNAs, extracted exosomes from two healthy women, one ovarian cystadenoma patient, and each two EOC patients at FIGO stage III and stage IV were verified on a western blot using antibodies specific for the exosomal marker CD63 and the miRNA binding protein AGO2. This evidence concerns the gene AGO2 and ovarian cystadenoma.